NCT04900129View on ClinicalTrials.gov

Inhalation of Vapor With Medication (Diclofenac Sodium, Menthol, Methyl Salicylate and N-Acetyl Cysteine) Reduces Oxygen Need and Hospital Stay in COVID-19 Patients - A Case Control Study

PHASE1CompletedINTERVENTIONAL
Enrollment

43

Participants

Timeline

Start Date

December 1, 2020

Primary Completion Date

December 30, 2020

Study Completion Date

December 30, 2020

Conditions
Covid19
Interventions
COMBINATION_PRODUCT

Menthol 0.02%, Methyl salicylate 0.05%, N- Acetyl cysteine 1.2 gm%, and Diclofenac sodium 1gm%

inhaled vapor containing Menthol 0.02%, Methyl salicylate 0.05%, N- Acetyl cysteine 1.2 gm%, and Diclofenac sodium 1gm% twice daily in addition to conventional treatment. That is, 100 gram of emulsion contain diclofenac sodium 1 gram, N-acetyl cysteine 1.2 gm, menthol 20 mg, and methyl salicylic acid 50 mg.

Trial Locations (1)

1207

HN Sarker, Barishal

All Listed Sponsors
lead

Sher-E-Bangla Medical College

OTHER

NCT04900129 - Inhalation of Vapor With Medication (Diclofenac Sodium, Menthol, Methyl Salicylate and N-Acetyl Cysteine) Reduces Oxygen Need and Hospital Stay in COVID-19 Patients - A Case Control Study | Biotech Hunter | Biotech Hunter